{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:50:12Z","timestamp":1790740212087,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Scynexis"},{"name":"Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n To evaluate the safety and efficacy of two dosing regimens of oral ibrexafungerp (formerly SCY-078), a novel orally bioavailable \u03b2-glucan synthase inhibitor, in subjects with invasive candidiasis versus the standard of care (SOC) and to identify the dose to achieve target exposure (15.4\u2009\u03bcM\u00b7h) in >80% of the intended population.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In a multinational, open-label study, patients with documented invasive candidiasis were randomized to receive step-down therapy to one of three treatment arms: two dosing regimens of novel oral ibrexafungerp or the SOC treatment following initial echinocandin therapy. Plasma samples were collected to evaluate exposure by population pharmacokinetic (PK) modelling. Safety was assessed throughout the study and global response at the end of treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Out of 27 subjects enrolled, 7 received ibrexafungerp 500\u2009mg, 7 received ibrexafungerp 750\u2009mg and 8 received the SOC. Five did not meet criteria for randomization. Population PK analysis indicated that an ibrexafungerp 750\u2009mg regimen is predicted to achieve the target exposure in \u223c85% of the population. The rate of adverse events was similar among patients receiving ibrexafungerp or fluconazole. Similar favourable response rates were reported among all groups: 86% (n\u205f=\u205f6) in the ibrexafungerp 750\u2009mg versus 71% (n\u205f=\u205f5) in both the fluconazole and ibrexafungerp 500\u2009mg treatment arms. The one subject treated with continued micafungin had a favourable global response.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The oral ibrexafungerp dose estimated to achieve the target exposure in subjects with invasive candidiasis is 750\u2009mg daily. This dose was well tolerated and achieved a favourable global response rate, similar to the SOC.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/jac\/dkz277","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T07:08:38Z","timestamp":1559891318000},"page":"3056-3062","source":"Crossref","is-referenced-by-count":88,"title":["MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis"],"prefix":"10.1093","volume":"74","author":[{"given":"Andrej","family":"Spec","sequence":"first","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pullman","sequence":"additional","affiliation":[{"name":"Mercury Street Medical, Butte, MT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of California-Davis, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Powderly","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis H","family":"Tobin","sequence":"additional","affiliation":[{"name":"Albany Medical Center, Albany, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Medical College of Georgia\/Augusta University, Augusta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A","family":"Wring","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Angulo","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Helou","sequence":"additional","affiliation":[{"name":"Scynexis, Inc., Jersey City, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Pappas","sequence":"additional","affiliation":[{"name":"University of Alabama, Birmingham, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Mycoses Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ostrosky-Zeichner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Shoham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Revankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mushatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Bedimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Freifeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Hong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Reboli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Pouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Almyroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Andes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katheen","family":"Mullane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"2019092005514052700_dkz277-B1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019092005514052700_dkz277-B2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3201\/eid0702.010203","article-title":"The impact of hospital-acquired bloodstream infections","volume":"7","author":"Wenzel","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"2019092005514052700_dkz277-B3","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.1086\/430923","article-title":"Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies","volume":"41 Suppl 6","author":"Wenzel","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2019092005514052700_dkz277-B4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019092005514052700_dkz277-B5","doi-asserted-by":"crossref","first-page":"e00435","DOI":"10.1128\/AAC.00435-17","article-title":"In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris","volume":"61","author":"Berkow","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019092005514052700_dkz277-B6","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/jac\/dkx010","article-title":"The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp","volume":"72","author":"Marcos-Zambrano","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019092005514052700_dkz277-B7","doi-asserted-by":"crossref","first-page":"e02396","DOI":"10.1128\/AAC.02396-16","article-title":"The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019092005514052700_dkz277-B8","doi-asserted-by":"crossref","first-page":"e00161","DOI":"10.1128\/AAC.00161-17","article-title":"Differential activity of the oral glucan synthase inhibitor SCY-078 against wild-type and echinocandin-resistant strains of Candida spp","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019092005514052700_dkz277-B9","doi-asserted-by":"crossref","first-page":"e01961","DOI":"10.1128\/AAC.01961-16","article-title":"SCY-078 is fungicidal against Candida species in time-kill studies","volume":"61","author":"Scorneaux","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019092005514052700_dkz277-B10","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2019092005514052700_dkz277-B11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01588-12","article-title":"In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods","volume":"57","author":"Pfaller","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019092005514052700_dkz277-B12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates","volume":"58","author":"Jimenez-Ortigosa","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019092005514052700_dkz277-B13","volume-title":"Abstracts of the Twenty-seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2017","author":"Roman"},{"key":"2019092005514052700_dkz277-B14","doi-asserted-by":"crossref","first-page":"e02068","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical pharmacokinetics and pharmacodynamic target of SCY-078, a first-in-class orally active antifungal glucan synthesis inhibitor, in murine models of disseminated candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019092005514052700_dkz277-B15","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/AAC.04445-14","article-title":"Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2019092005514052700_dkz277-B16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019092005514052700_dkz277-B17","volume-title":"Abstracts of ASM Microbe","author":"Murphy"},{"key":"2019092005514052700_dkz277-B18","volume-title":"Abstracts of ASM Microbe","author":"Murphy"},{"key":"2019092005514052700_dkz277-B19","volume-title":"Abstracts of the Twenty-seventh European Congress of Clinical Microbiology and Infectious Diseases","author":"Marcos-Zambrano"},{"key":"2019092005514052700_dkz277-B20","volume-title":"Abstracts of the Twenty-seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2017","author":"Marcos-Zambrano"},{"key":"2019092005514052700_dkz277-B21","volume-title":"Abstracts of the Twenty-seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2017","author":"Larkin"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz277\/28935189\/dkz277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/10\/3056\/30039450\/dkz277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T05:52:25Z","timestamp":1568958745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/10\/3056\/5532212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":21,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,7,15]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz277","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,7,15]]}}}